亚第尼基环酶增加了心肌病的存活率
David M Roth1, Hamed Bayat, Jeffrey D Drumm
1VA San Diego Healthcare System, San Diego, CA 92161, USA.
Circulation
|May 9, 2002
概括
心脏腺环酶VI型 (AC(VI)) 表达量的增加改善了存活率,并在Gq心肌病症中消除了心肌缩. 这项研究表明,AC(VI) 恢复了心脏功能,并增加了受影响小鼠的cAMP生成.
科学领域:
- 心血管生物学 心血管生物学
- 分子心脏病学分子心脏病学
- 基因工程是一种基因工程.
背景情况:
- Gq相关心肌病导致心脏cAMP生成的增加.
- 腺环酶VI型 (AC(VI)) 在心肌病中的生存和缩中的作用尚未完全理解.
研究的目的:
- 调查心脏AC(VI) 含量增加是否提高了Gq相关心肌病的存活率.
- 在Gq心肌病的背景下,评估AC(VI) 对心肌缩的影响.
主要方法:
- 交叉繁殖的小鼠患有Gq相关心肌病症和心脏指导的AC (VI) 表达.
- 评估Gq/AC,Gq和对照小鼠的存活率,心肌缩 (心室重量/阴茎长度,肌细胞大小),心脏功能 (尺寸,分数缩短) 和cAMP产量.
主要成果:
- 心脏指导的AC(VI) 表达显著增加了生存率 (P<0.0001).
- 与Gq小鼠相比,Gq/AC小鼠中的心肌缩和心脏扩张被废除 (P<0.01).
- Gq/AC小鼠表现出改善的心脏功能,包括减少末端透气直径 (P<0.05) 和增加分数缩短 (P<0.001),增强cAMP产生 (P<0.02).
结论:
- 心脏指导的AC(VI) 表达恢复了肌细胞的腺基环酶功能.
- AC(VI) 改善心脏功能,增加cAMP生成,并消除心肌缩.
- 在Gq心肌病症中,上调AC (VI) 显著增加了存活率.
相关概念视频
01:09GPCRs Regulate Adenylyl Cylase Activity
6.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.9K
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.4K
01:26Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
01:29Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
01:29Cardiomyopathy V: Interprofessional Care
753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753